Bukwang Pharm Subsidiary Concludes Corporate Rehabilitation Process Following Debt Repayment
Bukwang Pharm announced that its subsidiary, Korea Union Pharm, has successfully completed the court-supervised corporate rehabilitation process. This decision was made after the company fully repaid all of its outstanding debts.
Korea Union Pharm had been under court receivership for the past few years due to management difficulties. However, through this debt repayment, the company has secured financial stability and established a foundation for normalizing its operations.
Bukwang Pharm expects that the conclusion of its subsidiary's rehabilitation process will significantly help enhance the company's credibility. Furthermore, the company stated that it plans to focus more on pharmaceutical development and production within a stable management environment moving forward.
This news is being received as a positive signal by those in the pharmaceutical industry. Much attention is now focused on what steps Korea Union Pharm will take in the domestic pharmaceutical market following the completion of its rehabilitation process.